2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.
Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.
The first results from the RTOG 0424 study were presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.
The trial aimed to answer the question of the role of temozolomide and radiation in newly-diagnosed patients with low-grade gliomas. Though there was a substantial amount of data regarding the role of radiation in this setting, only anecdotal data existed about the role of temozolomide. Temozolomide, Lesser notes, is the most active drug in high-grade tumors.
The RTOG 0424 trial was initially thought to be a large randomized trial but was toned down due to the absence of early data. The single-arm RTOG 0424 trial treated about 125 high-risk low-grad glioma patients with the standard therapy (for high-grade glioma): radiation with temozolomide followed by adjuvant monthly temozolomide for 6-12 cycles.